BeyondSpring (NASDAQ:BYSI – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, Zacks reports.
BeyondSpring Stock Down 2.5%
NASDAQ BYSI traded down $0.06 during trading hours on Wednesday, hitting $2.15. The company’s stock had a trading volume of 21,833 shares, compared to its average volume of 36,546. BeyondSpring has a twelve month low of $0.98 and a twelve month high of $3.44. The firm has a market capitalization of $86.51 million, a P/E ratio of -21.45 and a beta of 0.26. The stock has a fifty day moving average of $1.85 and a 200 day moving average of $1.98.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of BeyondSpring in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Hedge Funds Weigh In On BeyondSpring
An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC lifted its holdings in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 256,212 shares of the company’s stock after purchasing an additional 231,844 shares during the quarter. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 as of its most recent SEC filing. Institutional investors own 40.29% of the company’s stock.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
Further Reading
- Five stocks we like better than BeyondSpring
- How is Compound Interest Calculated?
- CleanSpark Secures $1.15B, Stock Drops—Here’s Why It’s an Opportunity
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Bulls Should Want a Bigger Drop in Palantir Stock
- Short Selling – The Pros and Cons
- Papa John’s $2.7 Billion Takeover Bid: A Price on Untapped Value
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
